In a preclinical study, chronic exposure of colorectal cells to bevacizumab upregulated VEGF-A, -B, -C, PLGF, VEGFR1 expression and VEGFR1 phosphorylation, resulting to increased tumor cell migration and invasion and enhanced metastatic potential [214], highlighting the rationale of successfully blocking the VEGF/VEGFR pathway directly on tumor cells. The gene discussed is PGF; the disease is neoplasm.